ArticleScientific reports2026
The A2357T substitution in the kinase domain of yeast Tor1 confers growth promoting TORC1 activity independent of Gtr1/2 and Pib2.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The highly conserved Target of Rapamycin Complex 1 (TORC1) plays a central role in controlling eukaryotic cell growth in response to diverse environmental cues, including nitrogen availability. In yeast, TORC1 activity is stimulated through direct interaction with at least two upstream regulators: the Gtr1/2 GTPase complex, homologous to mammalian RagAB/CD and which binds the fungus-specific Tco89 protein, and the FYVE-domain-containing protein Pib2, an amino acid sensor. Here, using a novel genetic approach, we first confirmed that in cells expressing neither Gtr1/2 nor Pib2, no other factor is capable of supporting sufficient TORC1 activity to sustain cell growth, even under 25 different nitrogen supply conditions. We then identified a novel, dominant TOR1 mutation introducing an A2357T substitution into the Tor1 kinase domain and conferring sufficient TORC1 activity to support cell growth despite the loss of both Gtr1/2 and Pib2. Interestingly, previous studies have identified substitutions at the corresponding A2420 residue in human mTOR from multiple cancer cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.